- Aktuelle Seite:
-
Home
-
Substitutionsmittel
- Verschiedenes
Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine.
Noble F, Marie N.
Front Psychiatry. 2019 Jan 18;9:742. doi: 10.3389/fpsyt.2018.00742. eCollection 2018. Review.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345716/
Comparing opium tincture and methadone for medication-assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double-blind randomized controlled trial.
Nikoo M, Moazen-Zadeh E, Nikoo N, Javidanbardan S, Kazemi A, Choi F, Vogel M, Gholami A, Tavakoli S, Givaki R, Jazani M, Mohammadian F, Markazi Moghaddam N, Goudarzi N, Schutz C, Jang K, Akhondzadeh S, Krausz M.
Int J Methods Psychiatr Res. 2019 Feb 4:e1768. doi: 10.1002/mpr.1768.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30714249
Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?.
Marsden, J., Tai, B., Ali, R., Hu, L., Rush, A. J., and Volkow, N. (2019)
Addiction, doi.org/10.1111/add.14546.
https://onlinelibrary.wiley.com/doi/10.1111/add.14546
Temperamental Characteristics and Problem-Solving Skills among Patients on Opioid Agonists.
Eslami-Saaraab S, Eslami-Shahrbabaki H, Eslami-Shahrbabaki M, Motaghyan S.
Addict Health. 2018 Jan;10(1):24-31. doi: 10.22122/ahj.v10i1.579.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312562/
Change in alcohol and other drug use during five years of continuous opioid substitution treatment
Brian Eastwood, John Strang and John Marsden
Drug and Alcohol Dependence, Volume 194, 1 January 2019, Pages 438-446, doi.org/10.1016/j.drugalcdep.2018.11.008
https://www.sciencedirect.com/science/article/pii/S0376871618304897#bib0100
Substitution von A bis Z
Mit der vorliegenden Broschüre möchten wir Ihnen ein Nachschlagewerk an die Hand geben, welches die Grundlagen der Suchttherapie von A bis Z vermittelt und Ihnen daher im Alltag ein hilfreicher Begleiter sein kann. Vor allem Personen, die noch wenig Erfahrung mit der Substitutionsbehandlung haben, sollen unterstützt werden, sich schnell in das Therapiegebiet einzufinden und die Arbeitsabläufe kennen zu lernen. (Hexal, 2018)
Sanofi Kompendium Substitutionsmedizin – Neuauflage 2018
Das neue Kompendium Substitutionsmedizin bietet allen Ärzten, die in der Praxis mit Suchtmedizin zu tun haben, einen umfassenden Einblick in die verschiedenen Aspekte der Opiatsubstitutionstherapie. Das Kompendium wurde erweitert um die aktuelle Rechtslage und richtet sich auch an ApothekerInnen als zusätzliche Zielgruppe
Das Kompendium kann aufgerufen und runtergeladen werden auf der Substitutionsseite von Sanofi. Die Druckausgabe kann über den Außendienst von Sanofi bestellt werden.
https://www.substitutionsportal.de/
One size does not fit all – evolution of opioid agonist treatments in a naturalistic setting over 23 years.
Nordt, C., Vogel, M., Dey, M., Moldovanyi, A., Beck, T., Berthel, T., Walter, M., Seifritz, E., Dürsteler, K. M., and Herdener, M. (2018)
Addiction, doi.org/10.1111/add.14442.
Abstract
https://onlinelibrary.wiley.com/doi/10.1111/add.14442
SAMHSA. Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families: Treatment Improvement Protocol: TIP 63.
Substance Abuse and Mental Health Services Administration
[US] Substance Abuse and Mental Health Services Administration, 2018
https://store.samhsa.gov/shin/content/SMA18-5063FULLDOC/SMA18-5063FULLDOC.pdf
Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study.
Larney S, Hickman M, Fiellin DA, Dobbins T, Nielsen S, Jones NR, Mattick RP, Ali R, Degenhardt L.
BMJ Open. 2018 Aug 5;8(8):e025204. doi: 10.1136/bmjopen-2018-025204.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078240/
Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.
Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, Hser YI.
J Neuroimmune Pharmacol. 2018 Aug 9. doi: 10.1007/s11481-018-9801-x.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30094695
USA. FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder
The U.S. Food and Drug Administration today issued new scientific recommendations aimed at encouraging more widespread innovation and development of novel medication-assisted treatment (MAT) drugs for the treatment of opioid use disorder (OUD). New draft guidance issued today outlines new ways for drug developers to consider measuring and demonstrating the effectiveness and benefits of new or existing MAT products. This new draft guidance is part of the FDA’s ongoing commitment to promote more widespread development, access to and adoption of MAT. (FDA, 06.08.2018)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm615892.htm
Pharmacological therapies for management of opium withdrawal.
Rahimi-Movaghar A, Gholami J, Amato L, Hoseinie L, Yousefi-Nooraie R, Amin-Esmaeili M.
Cochrane Database Syst Rev. 2018 Jun 21;6:CD007522. doi: 10.1002/14651858.CD007522.pub2. Review.
Abstract
Snake Venom Use as a Substitute for Opioids: A Case Report and Review of Literature.
Mehra A, Basu D, Grover S.
Indian J Psychol Med. 2018 May-Jun;40(3):269-271. doi: 10.4103/IJPSYM.IJPSYM_216_17.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968650/
Continuous opioid substitution treatment over five years: Heroin use trajectories and outcomes.
Eastwood B, Strang J, Marsden J.
Drug Alcohol Depend. 2018 May 16;188:200-208. doi: 10.1016/j.drugalcdep.2018.03.052.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29778774
Opioid substitution treatment and heroin dependent adolescents: reductions in heroin use and treatment retention over twelve months.
Smyth BP, Elmusharaf K, Cullen W.
BMC Pediatr. 2018 May 4;18(1):151. doi: 10.1186/s12887-018-1137-4.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936020/
USA. Lofexidine: FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults
Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority. (FDA, USA, 16.05.2018)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607884.htm
Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review.
Maglione MA, Raaen L, Chen C, Azhar G, Shahidinia N, Shen M, Maksabedian E, Shanman RM, Newberry S, Hempel S.
J Subst Abuse Treat. 2018 Jun;89:28-51. doi: 10.1016/j.jsat.2018.03.001. Epub 2018 Mar 13.
https://linkinghub.elsevier.com/retrieve/pii/S0740-5472(17)30482-8
Characteristics of opioid-maintained clients smoking fentanyl patches: The importance of confirmatory drug analysis illustrated by a case series and mini-review.
Kimergård A, Dunne J, Bøgen A, Hindersson P, Breindahl T.
Drug Test Anal. 2018 Apr 19. doi: 10.1002/dta.2397.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29675893
Listening to Patients’ Voices in Developing New Opioid Addiction Treatments.
NIDA. (2018, April 5).
Alternative Opioid Agonists in the Treatment of Opioid Dependence: A Systematic Review [Internet].
Mosdøl A, Ding KY, Hov L.
Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Mar 8.
https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0098799/
Unsupervised Intake of Medicines for Individuals in Opioid Maintenance [Internet].
Hov L, Mosdøl A, Ding Y, Strømme H, Vist GE.
Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2016 Sep.
https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0098764/
Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.
Bansback, N., Guh, D., Oviedo-Joekes, E., Brissette, S., Harrison, S., Janmohamed, A., Krausz, M., MacDonald, S., Marsh, D. C., Schechter, M. T., and Anis, A. H. (2018)
Addiction, doi: 10.1111/add.14171.
Abstract
https://onlinelibrary.wiley.com/doi/abs/10.1111/add.14171
Neue Auflage: Leitfaden für Ärzte zur substitutionsgestützten Behandlung Opiatabhängiger (Bayerische Akademie für Sucht- und Gesundheitsfragen)
Die 4. vollständig überarbeitete Auflage der BAS-Publikation "Leitfaden für Ärzte zur substitutionsgestützten Behandlung Opiatabhängiger" steht Ihnen ab sofort zum Download zur Verfügung.
Hierbei wurden die neue BtMVV (2017) sowie die überarbeiteten Richtlinien der Bundesärztekammer (2017) berücksichtigt. (BAS, Januar 2018)
Handbuch Substitutionsbehandlung in Oberösterreich
Sachverständigenkommission zur regionalen Koordination der Substitutionsbehandlung
Linz, 2016, Version 2.0
Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities
Dennis McCarty, Kelsey C. Priest, P. Todd Korthuis
Annual Review of Public Health 2018 39:1
http://www.annualreviews.org/doi/pdf/10.1146/annurev-publhealth-040617-013526
Tramadol for maintenance in opioid dependence: A retrospective chart review.
Sarkar S, Lal R, Varshney M, Balhara YPS.
J Opioid Manag. 2017 Sep/Oct;13(5):329-334. doi: 10.5055/jom.2017.0401.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29199398
Kanada. B.C. pilot project to distribute clean opioids to people at high risk of overdose
Ottawa has approved a pilot project that will allow health officials in B.C. to distribute clean opioids to drug users to use as they please, marking one of the province's most radical efforts to address a fentanyl-saturated drug supply that has killed more than 1,000 people this year. (Globe and Mail, 19.12.2017)
Betäubungsmittel: Arzneimittel zur Substitution – ein Überblick
Bei der Substitutionstherapie Opioidabhängiger gibt es eine Reihe zusätzlicher Auflagen. Hier sind vor allem die Regelungen des § 5 der Betäubungsmittelverschreibungsverordnung maßgeblich. Unter anderem finden sich dort Vorgaben, welche Arzneimittel beziehungsweise Wirkstoffe überhaupt für eine Substitutionstherapie verschrieben werden können. In der Praxis stehen sowohl Rezepturen als auch Fertigarzneimittel zur Verfügung. (DAZ – Deutsche Apotheker Zeitung, 11.12.2017)
Opioid Agonist Treatment Reduces Societal Costs of Crime
Patients with opioid use disorder generated crime-related costs to society at a lower rate while they were in treatment compared with after they left treatment.
Patients who initiate time-unlimited opioid-agonist therapy will generate lower average total crime-related costs over the next 6 months than patients who initiate a 21-day detoxification regimen.
Savings in crime-related costs are substantial and warrant inclusion in cost-effectiveness analyses of treatment for opioid addiction. (NIDA Notes, Eric Sarlin, M.Ed., M.A., 23.08.2017)
Seite 1 von 3